-
Something wrong with this record ?
Coronary Arterial Spasm During Pulsed Field Ablation to Treat Atrial Fibrillation
VY. Reddy, J. Petru, M. Funasako, K. Kopriva, P. Hala, M. Chovanec, M. Janotka, S. Kralovec, P. Neuzil
Language English Country United States
Document type Journal Article
NLK
Free Medical Journals
from 1950 to 1 year ago
Open Access Digital Library
from 1950-01-01
Open Access Digital Library
from 1950-01-01
- MeSH
- Atrial Fibrillation * surgery MeSH
- Catheter Ablation * adverse effects MeSH
- Coronary Vessels diagnostic imaging surgery MeSH
- Humans MeSH
- Nitroglycerin therapeutic use MeSH
- Heart Atria MeSH
- Pulmonary Veins * MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Pulsed field ablation (PFA) has a unique safety profile when used to treat atrial fibrillation, largely related to its preferentiality for myocardial tissue ablation, in particular, esophageal sparing. A pentaspline catheter was the first such PFA system studied clinically for atrial fibrillation ablation; in these initial regulatory trials, the catheter was used for pulmonary vein isolation and left atrial posterior wall ablation. Since its regulatory approval in Europe, in clinical practice, physicians have ablated beyond pulmonary vein isolation and left atrial posterior wall ablation to expanded lesion sets in closer proximity to coronary arteries. This is an unstudied important issue because preclinical and clinical data have raised the potential for coronary arterial spasm. Herein, we studied the vasospastic potential of PFA lesion sets, both remote from and adjacent to coronary arteries. METHODS: During routine atrial fibrillation ablation using the pentaspline PFA catheter, coronary angiography was performed before, during, and after pulsed field applications. The lesion sets studied included: (1) those remote from the coronary arteries such as pulmonary vein isolation (n=25 patients) and left atrial posterior wall ablation (n=5), and (2) ablation of the cavotricuspid isthmus (n=20) that is situated adjacent to the right coronary artery. RESULTS: During pulmonary vein isolation and left atrial posterior wall ablation, coronary spasm did not occur, but cavotricuspid isthmus ablation provoked severe subtotal vasospasm in 5 of 5 (100%) consecutive patients, and this was relieved by intracoronary nitroglycerin in 5.5±3.5 minutes. ST-segment elevation was not observed. However, no patient (0%, P=0.004) had severe spasm if first administered parenteral nitroglycerin, either intracoronary (n=5) or intravenous (n=10), before treatment. CONCLUSIONS: Coronary vasospasm was not provoked during PFA at locations remote from coronary arteries, but when the energy is delivered adjacent to a coronary artery, PFA routinely provokes subclinical vasospasm. This phenomenon is attenuated by nitroglycerin, administered either post hoc to treat spasm or as prophylaxis.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032190
- 003
- CZ-PrNML
- 005
- 20230131151112.0
- 007
- ta
- 008
- 230120s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1161/CIRCULATIONAHA.122.061497 $2 doi
- 035 __
- $a (PubMed)36134574
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Reddy, Vivek Y $u Homolka Hospital, Prague, Czech Republic (V.Y.R., J.P., M.F., K.K., P.H., M.C., M.J., S.K., P.N.) $u Icahn School of Medicine at Mount Sinai, New York (V.Y.R.) $1 https://orcid.org/0000000256384993
- 245 10
- $a Coronary Arterial Spasm During Pulsed Field Ablation to Treat Atrial Fibrillation / $c VY. Reddy, J. Petru, M. Funasako, K. Kopriva, P. Hala, M. Chovanec, M. Janotka, S. Kralovec, P. Neuzil
- 520 9_
- $a BACKGROUND: Pulsed field ablation (PFA) has a unique safety profile when used to treat atrial fibrillation, largely related to its preferentiality for myocardial tissue ablation, in particular, esophageal sparing. A pentaspline catheter was the first such PFA system studied clinically for atrial fibrillation ablation; in these initial regulatory trials, the catheter was used for pulmonary vein isolation and left atrial posterior wall ablation. Since its regulatory approval in Europe, in clinical practice, physicians have ablated beyond pulmonary vein isolation and left atrial posterior wall ablation to expanded lesion sets in closer proximity to coronary arteries. This is an unstudied important issue because preclinical and clinical data have raised the potential for coronary arterial spasm. Herein, we studied the vasospastic potential of PFA lesion sets, both remote from and adjacent to coronary arteries. METHODS: During routine atrial fibrillation ablation using the pentaspline PFA catheter, coronary angiography was performed before, during, and after pulsed field applications. The lesion sets studied included: (1) those remote from the coronary arteries such as pulmonary vein isolation (n=25 patients) and left atrial posterior wall ablation (n=5), and (2) ablation of the cavotricuspid isthmus (n=20) that is situated adjacent to the right coronary artery. RESULTS: During pulmonary vein isolation and left atrial posterior wall ablation, coronary spasm did not occur, but cavotricuspid isthmus ablation provoked severe subtotal vasospasm in 5 of 5 (100%) consecutive patients, and this was relieved by intracoronary nitroglycerin in 5.5±3.5 minutes. ST-segment elevation was not observed. However, no patient (0%, P=0.004) had severe spasm if first administered parenteral nitroglycerin, either intracoronary (n=5) or intravenous (n=10), before treatment. CONCLUSIONS: Coronary vasospasm was not provoked during PFA at locations remote from coronary arteries, but when the energy is delivered adjacent to a coronary artery, PFA routinely provokes subclinical vasospasm. This phenomenon is attenuated by nitroglycerin, administered either post hoc to treat spasm or as prophylaxis.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a fibrilace síní $x chirurgie $7 D001281
- 650 _2
- $a koronární cévy $x diagnostické zobrazování $x chirurgie $7 D003331
- 650 12
- $a venae pulmonales $7 D011667
- 650 12
- $a katetrizační ablace $x škodlivé účinky $7 D017115
- 650 _2
- $a srdeční síně $7 D006325
- 650 _2
- $a nitroglycerin $x terapeutické užití $7 D005996
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Petru, Jan $u Homolka Hospital, Prague, Czech Republic (V.Y.R., J.P., M.F., K.K., P.H., M.C., M.J., S.K., P.N.)
- 700 1_
- $a Funasako, Moritoshi $u Homolka Hospital, Prague, Czech Republic (V.Y.R., J.P., M.F., K.K., P.H., M.C., M.J., S.K., P.N.)
- 700 1_
- $a Kopriva, Karel $u Homolka Hospital, Prague, Czech Republic (V.Y.R., J.P., M.F., K.K., P.H., M.C., M.J., S.K., P.N.)
- 700 1_
- $a Hala, Pavel $u Homolka Hospital, Prague, Czech Republic (V.Y.R., J.P., M.F., K.K., P.H., M.C., M.J., S.K., P.N.)
- 700 1_
- $a Chovanec, Milan $u Homolka Hospital, Prague, Czech Republic (V.Y.R., J.P., M.F., K.K., P.H., M.C., M.J., S.K., P.N.)
- 700 1_
- $a Janotka, Marek $u Homolka Hospital, Prague, Czech Republic (V.Y.R., J.P., M.F., K.K., P.H., M.C., M.J., S.K., P.N.)
- 700 1_
- $a Kralovec, Stepan $u Homolka Hospital, Prague, Czech Republic (V.Y.R., J.P., M.F., K.K., P.H., M.C., M.J., S.K., P.N.)
- 700 1_
- $a Neuzil, Petr $u Homolka Hospital, Prague, Czech Republic (V.Y.R., J.P., M.F., K.K., P.H., M.C., M.J., S.K., P.N.) $1 https://orcid.org/0000000343348165
- 773 0_
- $w MED00001091 $t Circulation $x 1524-4539 $g Roč. 146, č. 24 (2022), s. 1808-1819
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36134574 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151108 $b ABA008
- 999 __
- $a ok $b bmc $g 1891133 $s 1183525
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 146 $c 24 $d 1808-1819 $e 20220922 $i 1524-4539 $m Circulation (New York, N.Y.) $n Circulation (New York) $x MED00001091
- LZP __
- $a Pubmed-20230120